**PLAQUE**TEC

Unique Coronary Liquid Biopsy Platform

A New Paradigm in Cardiovascular Risk Management

Coronary Artery Disease is the single biggest killer globally

20th Century Death

CARDIOVASCULAR DISEASES 1,246m

Coronary artery disease 540m

Stroke 410m

Other cardio-vascular 178m

99% of Americans need to improve their heart health.

1 of every 3 deaths in the United States is caused by heart disease.

Each year, an estimated 785,000 people will have their first heart attack.

Every 39 seconds someone dies from heart disease and stroke.

PLAQUETEC

Cardiologists will use coronary biomarkers to predict patients' risk of future events

How do we assess risk now?

## How will we assess risk in 5 years?

Pharma will utilise biomarker data to de-risk next-generation CVD pipeline therapies

Now: patent expiry & late-stage pipeline failures

Off patent 2011

Off patent 2016

Phase III failure

Torcetrapib

Pfizer

≠

Future: mechanistic biomarker data de-risks trials

PLAQUETEC

Committed to changing the current SOC in the diagnosis, prevention, and treatment of CAD

PlaqueTec is pioneering a biomarker-based approach to transforming CAD care

What we've done

2008   Liquid Biopsy System (LBS) prototype developed

2010   First LBS clinical trial

2012   Launched first in-human studies

2014   Received CE Mark

2016   First biomarker data presented

**2017**   Data published in JACC, Basic to Translational Science (December)

Where we're headed

✓ Identifying plaque-based inflammatory biomarkers

✓ Developing bespoke assays

✓ Linking biomarkers to clinical outcomes

✓ Driving the use of PlaqueTec assays and data to develop new CAD therapies

●PLAQUETEC

Disruptive technology that allows liquid biopsy at the site of coronary plaque


Location of plaque in artery

Local biomarker release

Plaque-derived biomarkers trapped in boundary layer

LBS tracks over guidewire

Catheter takes seconds to position & deploy in artery

'Baffles' disrupt boundary layer; simultaneous sampling at 4 points

Samples downstream will contain plaque-related biomarkers

Differences (or gradients) detected will identify plaque-specific biomarkers

» Full video animation at www.plaquetec.com «

PLAQUE*TEC*

# A platform approach to transform CAD diagnosis and management

PlaqueTec Platform

DEVICE	RESEARCH PORTAL	DISEASE ACTIVITY ASSAYS	PROGNOSTIC DATA

Liquid Biopsy System (LBS)

Functional database

Central Laboratory Tests

Predictors of outcome

Proven presence of *gradients* of CAD inflammatory biomarkers

West NEJ, et al. *J Am Coll Cardiol Basic Trans Science.* 2017; 2: 646-54.

Summary

PlaqueTec Liquid Biopsy, a routine intervention to optimise the personalised care of patients with coronary artery disease

Renewed momentum in exploring the residual risk of patients living with CVD

The academic community is looking for new approaches to personalised diagnostics and tailored interventions

The new PlaqueTec catheter will be ready for clinical use in Q4 2018

New team and leadership focused on science, medicine and commercialisation

New capital will secure the bridge to significant value inflection as data drives adoption of the catheter globally and unlocks strategic partnerships

PLAQUETEC

PlaqueTec Ltd
The Cardiothoracic Bioincubator
Papworth Hospital, Papworth Everard
Cambridge CB23 3RE, United Kingdom

A new frontier in the treatment of cardiovascular disease